Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir

Frontiers in Medicine

article

Tatsuhiko Wada¹  Kosuke Shimode¹  Takayuki Hoshiyama²  Yoko Takayama²  Kunihiro Yamaoka¹ 

[1] Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine;Department of Infection Control and Prevention, Kitasato University Hospital

关键词: COVID-19;    Lopinavir;    Ritonavir;    elderly patient;    hyponatremia;    cruise ship;   

DOI  :  10.3389/fmed.2020.00241

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Following the first case of Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov-2), in Wuhan, China, in December 2019, it has spread worldwide. An outbreak in Japan occurred on a cruise ship, and this was followed by community-acquired COVID-19. Herein, we report three cases of COVID-19 that presented pneumonia following admission to Kitasato University Hospital. Patients were admitted based on the positive result of real-time reverse transcriptase–polymerase chain reaction (RT-PCR) tests for COVID-19 nucleic acid. All patients were diagnosed as suffering from non-severe COVID-19 pneumonia and were successfully treated with Lopinavir/Ritonavir (LPV/r). LPV/r could be an option for treating non-severe COVID-19 pneumonia in general and even in elderly patients.

【 授权许可】

CC BY